Raksha Jain1, Arthur Baines2, Umer Khan2, Brandie D Wagner3, Scott D Sagel4. 1. Department of Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas 75390-8558, TX, USA. Electronic address: raksha.jain@utsouthwestern.edu. 2. Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA. 3. Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA. 4. Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA.
Abstract
INTRODUCTION: Biomarkers of inflammation in blood and sputum can play a critical role in anti-inflammatory drug development in cystic fibrosis (CF). The objectives of this analysis were to examine relationships between airway and systemic measurements of inflammation, associations between inflammatory biomarkers and FEV1, differences in airway and systemic inflammation by baseline covariates, reproducibility of serum biomarkers, and to assess the effects of freezing and delayed processing on sputum analyte measurements. METHODS: We analyzed baseline and serial concentrations of inflammatory markers in blood and induced sputum collected from individuals with CF ages 10 years and older who participated in a multicenter clinical trial. RESULTS: Among circulating biomarkers, serum high sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) correlated most strongly with each other (rs = 0.85). Comparing sputum-based inflammation measurements, sputum neutrophil elastase and myeloperoxidase (MPO) were the most highly correlated (rs = 0.88). Markers most strongly correlated with ppFEV1 were serum hsCRP (rs = -0.55), SAA (rs =-0.58), and sputum neutrophil elastase (rs = -0.53). Within-subject standard deviation was consistently lower than between-subject standard deviation for all serum biomarkers. Serum calprotectin and MPO had the highest ratio of between-to-within subject variability. Freezing and delayed sputum processing were not associated with significant differences in measurements of sputum neutrophil elastase, IL-1β, or MPO. CONCLUSIONS: Among the biomarkers analyzed, serum hsCRP and sputum neutrophil elastase are promising candidates to include in CF anti-inflammatory clinical trials to avoid redundancy, minimize variation, and serve as correlates of lung disease severity and change.
INTRODUCTION: Biomarkers of inflammation in blood and sputum can play a critical role in anti-inflammatory drug development in cystic fibrosis (CF). The objectives of this analysis were to examine relationships between airway and systemic measurements of inflammation, associations between inflammatory biomarkers and FEV1, differences in airway and systemic inflammation by baseline covariates, reproducibility of serum biomarkers, and to assess the effects of freezing and delayed processing on sputum analyte measurements. METHODS: We analyzed baseline and serial concentrations of inflammatory markers in blood and induced sputum collected from individuals with CF ages 10 years and older who participated in a multicenter clinical trial. RESULTS: Among circulating biomarkers, serum high sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) correlated most strongly with each other (rs = 0.85). Comparing sputum-based inflammation measurements, sputum neutrophil elastase and myeloperoxidase (MPO) were the most highly correlated (rs = 0.88). Markers most strongly correlated with ppFEV1 were serum hsCRP (rs = -0.55), SAA (rs =-0.58), and sputum neutrophil elastase (rs = -0.53). Within-subject standard deviation was consistently lower than between-subject standard deviation for all serum biomarkers. Serum calprotectin and MPO had the highest ratio of between-to-within subject variability. Freezing and delayed sputum processing were not associated with significant differences in measurements of sputum neutrophil elastase, IL-1β, or MPO. CONCLUSIONS: Among the biomarkers analyzed, serum hsCRP and sputum neutrophil elastase are promising candidates to include in CF anti-inflammatory clinical trials to avoid redundancy, minimize variation, and serve as correlates of lung disease severity and change.
Authors: James F Chmiel; Michael W Konstan; Frank J Accurso; James Lymp; Nicole Mayer-Hamblett; Donald R VanDevanter; Lynn M Rose; Bonnie W Ramsey Journal: J Cyst Fibros Date: 2015-04-11 Impact factor: 5.482
Authors: Theodore J Torphy; Janet Allen; André M Cantin; Michael W Konstan; Frank J Accurso; Elizabeth Joseloff; Felix A Ratjen; James F Chmiel Journal: Ann Am Thorac Soc Date: 2015-09
Authors: H C Lai; S C FitzSimmons; D B Allen; M R Kosorok; B J Rosenstein; P W Campbell; P M Farrell Journal: N Engl J Med Date: 2000-03-23 Impact factor: 91.245
Authors: Philip H Quanjer; Sanja Stanojevic; Tim J Cole; Xaver Baur; Graham L Hall; Bruce H Culver; Paul L Enright; John L Hankinson; Mary S M Ip; Jinping Zheng; Janet Stocks Journal: Eur Respir J Date: 2012-06-27 Impact factor: 16.671
Authors: Scott D Sagel; Umer Khan; Raksha Jain; Gavin Graff; Cori L Daines; Jordan M Dunitz; Drucy Borowitz; David M Orenstein; Ibrahim Abdulhamid; Julie Noe; John P Clancy; Bonnie Slovis; Michael J Rock; Karen S McCoy; Steven Strausbaugh; Floyd R Livingston; Konstantinos A Papas; Michele L Shaffer Journal: Am J Respir Crit Care Med Date: 2018-09-01 Impact factor: 30.528
Authors: Jordana E Hoppe; Brandie D Wagner; J Kirk Harris; Steven M Rowe; Sonya L Heltshe; Emily M DeBoer; Scott D Sagel Journal: J Cyst Fibros Date: 2022-04-16 Impact factor: 5.527